# Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata

> **NCT04034134** · PHASE2 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 111 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** Jaktinib Hydrochloride Tablets
- **DRUG:** Jaktinib Hydrochloride Tablets
- **DRUG:** Jaktinib Hydrochloride Tablets

## Key facts

- **NCT ID:** NCT04034134
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-18
- **Primary completion:** 2021-11-26
- **Final completion:** 2021-11-26
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2022-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04034134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04034134, "Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04034134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*